Merck Announces New Data from KEYNOTE-028 Trial Evaluating KEYTRUDA Across Range of Cancer Types, Presented at 2015 ECC

By: via Benzinga
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new findings from the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.